The role of early life gut microbiota composition in the development of allergic diseases

Maimaiti Tuniyazi[1], Shuang Li[1], Xiaoyu Hu[1], Naisheng Zhang[1], and Yunhe Fu[1]

[1]Jilin University

May 5, 2022

Abstract

Allergic diseases are becoming a major healthcare issue in many developed nations, where living environment and lifestyle are most predominantly distinct. Such differences include urbanized, industrialized living environments, overused hygiene products, antibiotics, stationary lifestyle, and fast-food based diets tend to reduce microbial diversity and lead to impared immune protection, which further increase the development of allergic diseases. In the same time, studies also showed that modulating microbiomes can ameliorate allergic symptoms. Therefore, in this paper, we aimed to review recent findings on the potential role of the human microbiome in the gastrointestinal tract, surface of skin and respiratory tract for the development of allergic diseases. Furthermore, we addressed a potential therapeutic or even preventive strategy for such allergic diseases by modulating the human microbial composition.

The role of early life gut microbiota composition in the development of allergic diseases

Maimaiti Tuniyazi, Shuang Li, Xiaoyu Hu, Naisheng Zhang*, Yunhe Fu*

* Correspondence to: Yunhe Fu, E-mail: tuyhun103@gmail.com.

* Correspondence to: Naisheng Zhang, E-mail: zhangns@jlu.edu.cn (N. Zhang).

Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, 130062, People's Republic of China.

Abstract

Allergic diseases are becoming a major healthcare issue in many developed nations, where living environment and lifestyle are most predominantly distinct. Such differences include urbanized, industrialized living environments, overused hygiene products, antibiotics, stationary lifestyle, and fast-food based diets tend to reduce microbial diversity and lead to impared immune protection, which further increase the development of allergic diseases. In the same time, studies also showed that modulating microbiomes can ameliorate allergic symptoms. Therefore, in this paper, we aimed to review recent findings on the potential role of the human microbiome in the gastrointestinal tract, surface of skin and respiratory tract for the development of allergic diseases. Furthermore, we addressed a potential therapeutic or even preventive strategy for such allergic diseases by modulating the human microbial composition.

Introduction

Recent decades, allergic diseases such as asthma, atopic dermatitis (AD), and food allergy (FA) have become a major healthcare issue in many western countries and developed nations around the world(1,2). Studies identified that genetic and environmental factors are the main causes of allergy, however need more exploration.

Allergy is positively related to the degree of development of human society, where living environment and lifestyle are most predominantly distinct. Such changes include urbanized and industrialized living environments with overused hygiene products and antibiotics, coupled with stationary lifestyle and fast-food based diets. All such factors result in reduced microbial diversity in early life(3), which according to ecosystem theory, leads to impared immune protection and recovery of normal microbial communities(4).

The human microbiome has become an increasingly popular area of study due to its role in host physical and mental health and metabolism(5,6), which comprises bacteria, viruses, fungi, prozonas, and archaea. Although human microbiome can be found on the surfaces of skin, respiratory and reproductive tracts, it is primarily colonized in the gastrointestinal tract. Accumulating evidence indicates that the human microbiome plays an important role in the development and prevention of allergic diseases. Commensal microbial communities in gastrointestinal tract and other organs have shown to modulate both innate and acquired immune responses via various axes, including gut lung axis, gut skin axis. Recent studies showed that numerous environmental factors can affect the microbiome colonization, composition and metabolic activity in early life, and modify the host functions for digestion and nutrient absorption for host energy production and immune modulation and protection(7–10). Naturally, early life microbiota colonization with healthy microbiota with proper diversity and abundance is a critical factor in the later development of immune protection in infants. On the contrary, dysbiosis of the microbiome is associated with greater disease susceptibility and immune-related disorders later in life, including allergic diseases(11–13).

Bacteria, previously, were considered as pathogens, however, it is evident that they have a crucial role in host physiology. Recent advances in cultural-independent DNA-sequencing technology (i.e. 16S rRNA sequencing) and data analysis methods revealed that every part of the human body is colonized with different microbial species which plays a complex role in the pathogenesis of FA, AD, and asthma. In this paper, we aimed to review recent findings on the potential role of the human microbiome in the gastrointestinal tract, surface of skin and respiratory tract for the development of allergic diseases. Furthermore, we addressed a potential therapeutic or even preventive strategy for such allergic diseases by modulating the human microbial composition.

Factors influencing early life gut microbiota

Numerous studies showed that the mammalian begins microorganism colonization during birth, and its composition can be influenced by several prenatal and postnatal environmental and host related factors which have vital roles in the development of a healthy immune system. Among such factors (Figure 1), delivery methods (vaginal or cesarean section delivery)(14–16), feeding choices (breast or bottle feed)(17), antibiotic or probiotic use(18,19), and other meanings of early gut microbiota modulation by vaginal fluid or fecal microbiota transplantation(20–22), can dramatically change the gut microbiota composition and modulate the infant's immune development and tolerances to different antigens. Delivery mode determines the colonization of early life microbiota in infants. For example, babies born by cesarean section lack commensal microbial communities that can be found in vaginal born infants. Instead, such delivery approaches result in colonization of pathogenic bacteria such as Enterococcus, Enterobacter, and Klebsiella species that are typically found in the hospital environment(23). Although such microbial gap mainly closed after 6 to 9 months of breastfeeding (except for Bacteroides, remain absent or very low level in most cesarean section infants), cesarean section delivery can increase the susceptibility of respiratory infectious disease in the first year of life, which determined by the first week of microbial colonization(24).

In the early age, infants have microbiomes that are similar to their mothers' vaginal microbiomes which mainly consist of Lactobacillus species suggesting that the infants might have obtained a certain part of their microbiota from the birth canal. However, it is also reported that Lactobacillus and Strepococci are found with high numbers in mother's milk(25), indicating breastfeeding has a significant impact on the infant gut microbial composition. Weaning (breastmilk) plays a role as an additional inoculum of the infant gut(26), which not only has microbes but also enriches bacterial species such as Bifidobacterium (utilizing nutrients in breastmilk). These bacteria, as the first arrivers in the infant intestinal tract, consume all the oxygen and create a suitable anaerobes condition for further colonization of other species that are characterized in the

2

healthy adult gut microbial community. Microbiomes in such babies that are born vaginally and fed with breast milk are termed as healthy microbiomes with highest abundance of Bifidobacteria and lowest number of opportunistic pathogenic bacteria such as Clostridium difficile and Escherichia coli(27–30).

Early life antibiotic use both in pregnancy and postnatal influence the establishment of normal infant gut microbiota and increase development of allergic diseases(31,32). Infants from mothers exposed to antibiotics during delivery showed a decreased microbial diversity compared to non-exposed infants. The microbiota of infants exposed to antibiotics was characterized by a decreased abundance of Bacteroidetes and Bifidobacteria, with a concurrent increase of Proteobacteria, which were most pronounced in terms of vaginally born infants. Furthermore, antibiotics administered during pregnancy and labor have been associated with an elevated risk of atopy, asthma, allergy and obesity.

Probiotics, vaginal and/or fecal microbiota transplantation are three major methods to modulate early life gut microbiota in infants and resulted in favorable outcomes especially in the preventive effect of disease development that may occur later in life(21,22,33). However, it is worthy of mentioning that such microbial modulation therapies are a time sensitive issue. According to previous reports(34,35), 1000 days of infant life, beginning from conception to 2 years of age, is a vital window of opportunity for microbiome modulation. The infant gut microbiota becomes more mature and individual both in functions and compositions after this period. Later in life, gut microbiota are mostly influenced by antibiotic or probiotic, antibiotic use, dietary change and FMT, and all of them can alter immune responses thereby changing the host's ability to defend diseases including allergic, infectious and autoimmune disorders.

The role of gut microbiota in the development of immune protection

The infant's gut microbiota is relatively much less populated compared to adults and its initial composition greatly affects the host whether it could develop proper immune responses to protect from various diseases later in life (Figure 2.). A study involved 14572 children(49), among them 10220 received at least 1 antibiotic treatment during the first 2 years of life, showed that early antibiotic exposure was associated with an increase risk of childhood asthma, allergic rhinitis, atopic dermatitis, celiac disease, overweight, obesity, and attention deficit hyperactivity disorder. Although such links are also influenced by the quantity, type, and timing of antibiotic exposure, any disruptions of gut microbiota result in increased susceptibility of various disorders. Germ-free experimental animals are best for studying the role of gut microbiota. Such studies have proved that there is a codependent relationship between gut microbiota and immune system development(50–60).

In human studies, in terms of allergic diseases, gut microbiota showed a vital role in the establishment of adaptive and innate immunity protection. For example, compared to healthy infants, babies with lower IgG responses to specific clusters of microbiota antigens are closely related to the development of allergic diseases including asthma, AD, and FD(12,61,62). Studies showed that infants with high risk of AD are associated with lower abundance of Proteobacteria with increased Toll-like receptors (TLR)-4 induced innate inflammatory responses, while depletion of Ruminococcaceae is associated with increased TLR-2 induced innate inflammatory responses(63–65). Recent years, the role of gut microbiota in asthma has become prominent. Indeed, infants that at a greater rate of developing asthma had lower abundance of some gut bacterial taxa such as Faecalibacterium and Bifidobacterium(66,67). Similarly, food allergy in early age is also closely related to reduced gut microbial abundance(12). Such studies suggest that modulating gut microbiota to a normal composition with proper abundance and function may be a novel method for promoting regulatory tolerogenic immune responses.

The role of lung and gut microbiota in asthma

Asthma is one of the most serious allergic diseases both in children and adults in the developed world currently affecting 300 million and increasing every year(76). Its connection to the gut microbiota was established decades ago, and studies indicated that early life antibiotic exposure, diet, formula feeding, cesarean-section, and polluted environment that directly involve in altering gut microbiota could aggravate asthma. Especially in the first year of life when the maturation of gut microbiota occurs, any disruptions during this period of development may cause asthma and other immunological diseases(77–90). According to a previous study(66),

3

gut microbiota of neonates is closely related to developing allergic diseases, the lowest relative abundance of Bifidobacteria, Akkermansia, and Faecalibacterium genera and higher relative abundance of Candia and Rhodotorula fungi have the highest risk of developing atopy and asthma. Therefore, such data suggests that the complex and dynamic nature of the gut microbiota may be an important factor in the development of asthma symptoms.

In addition to gut microbiota, mounting evidence suggests that the lung microbiota is also involved in the onset of respiratory diseases, especially in early life(91–94). This connection is supported by not only preclinical trials but also case-controlled animal experiments(95–97).

Healthy lungs predominantly colonized with commensal bacterial phylum such as Bacteroides and Prevotella spp.(98,99). Similar to gut microbiota, lung microbiota has a critical period of 2 weeks, during which it promotes the transient expression of programmed death ligand 1 (PDL1) in dendritic cells which is vital for the Treg-mediated attenuation of allergic airway responses(100). Exposing children to a diverse microbial environment is important for establishing a healthy immune response. Studies show that children who grow up in farms(73,88,101), where they have much more contact with microorganisms compared to urban environments, have a lower rate of developing allergic diseases. Studies also indicated that early life respiratory tract colonization with certain bacteria, such as Streptococcus, Moraxella, or Haemophilus increases the severity of lower respiratory viral infection in the first year of life, and risk of developing asthma symptoms later in life(102).

Asthma is not a single disease. It involves 2 major elements: the mother and the baby (Figure 3). Each of them has an individual or combined contribution to the development of asthma. On the other hand, such complexity also creates more opportunity for treating and preventing asthma during pregnancy and early life by various approaches. For example, antibiotic use during pregnancy increases asthma susceptibility in children, however, the severity of asthma may depend on the dose, type and timing of their usage(36,40,49,103–105). Such human studies are also proven in animal experiments(106). Therefore, careful use of antibiotics during pregnancy could alleviate asthma symptoms in the offspring. After delivery, during the window of opportunity, modulating gut microbiota via different methods, including probiotic supplement(106–109), fecal or vaginal microbiota transplantation(22,110,111), can ameliorate asthma in children. From the standpoint of exposing infants to diverse microbiomes, raising children in a farming environment, a big family or with pets could also increase tolerance of allergens thereby decreasing allergic diseases including asthma.

At the same time, most direct approach may be supplementing short chain fatty acid (SCFA), which can promote the maturation of dendritic cell in the bone marrow, leading to mature cells with reduced ability to instigate Th2 responses in the lung and to induce IgA production by mucosal B cells(112). SCFAs, especially butyrate acid produced by dietary fiber fermat's with the presence of Faecalibacterium prausnitzii(113), have an anti-inflammatory role and can promote epithelial barrier permeability.

The role of skin and gut microbiota in atopic dermatitis

AD, a chronic inflammatory skin disease, is also a major issue we are facing in the modern days, which affects 15-30% of children and 10% of adults(114). Its pathogenesis remains obscure(115), but it is considered as a result of a complex combination of the immune response, impaired barrier function, and microbiota elements. Among those factors, skin and gut microbiota seem to be more directly related to the development of AD (Figure 4.). Studies showed that changes in skin microbiota immune modulation due to disturbances in epidermal barrier function(116). Skin microbiota composition is mainly influenced by age, gender, ethnicity, climate, ultraviolet exposure, and lifestyle(117). Healthy skin surface is colonized with commensal microbiota such as Propionibacterium species, Corynebacterium and Staphylococcus.

AD is a complex skin disorder resulting from epidermal barrier dysfunction, altered innate/adaptive immune responses and imapried skin microbial biodiversity(118). Indeed, healthy skin microbiota protects the surface from various diseases including acute and chronic AD. When the skin microbiota loses microbial diversity(119), with the predominance of the Staphylococcus aureus over Staphylococcus epidermidis, AD happens. Studies also showed that skin microbiota diversity is also related to AD and the risk of allergic

sensitization to common allergens(120).

Similar to gut and lung microbiota, the composition of skin microbiota at an early age is also related to AD. For instance, a study showed that 2 months old babies with lower abundance of Staphylococci species on their skin had a lower risk of developing AD at 1 year(121). This is due to early life colonization of the skin by Staphylococci epidermidis is associated with the induction of specific Tregs that modulate activation of host immune responses locally(122).

Interestingly, unlike other allergic diseases, AD is not or poorly associated with cesarean delivery(123–125). Such data further indicated the role of skin microbiota in the development of AD. Because studies showed that in the hospital environment, especially in the operating room, it is predominated by bacteria such as *Staphylococcus* and *Corynebacterium(126), which are healthy skin microbiota* . Therefore, first connecting with healthy skin microbiota could act as a shield for resisting colonization of bacteria that may induce AD. Based on such results, skin microbiota modulation via probiotics or healthy skin microbiota may provide us a novel therapeutic approach for alleviating AD symptoms(127).

Recent studies indicated that gut microbiota is associated with immune modulation as a factor of AD development(128,129). Data showed that the severity of AD is closely related to abundance of certain bacteria. For example, a study indicated that compared to healthy controls, people with AD have a lower density of Bifidobacterium in their intestinal tract(130). However, the count and percentage of *Bifidobacterium is* different according to the stage of AD. Early gut microbiota colonization is associated with various diseases, including AD. For example, Clostridium difficile was related to the development of AD while lower abundance of Bacteroidetes at 1 month of age was associated with AD at 2 years of age(131–133). A recent study showed that compared to healthy school children, the gut of patients with AD was significantly less abundant in some bacterial species, namely Lachnobacterium and Faecalibacterium(134). Such studies highlight the possibility of preventing and treating AD by modulating gut microbiota. Indeed, evidence suggested that oral supplementation of Lactobacillus and Bifidobacterium strains could reduce the risk of AD in infants by regulating T cell-mediated responses(135). FMT, as the most direct approach of modulating gut microbiota, is reported to be associated with suppression of AD-induced allergic responses by restoration of gut microbiota and immunological balance both in human and animal studies(136,137).

The role of (oral and) gut microbiota in food allergy

It is obvious that oral and gut microbiomes are closely related to food allergies (Figure 5.). The oral mucosa is the first contactor of antigens and is the beginning of a continuous gastrointestinal ecosystem that contains local antigen-presenting cells, lymphoid cells, and associated with organizing lymphoid structures(138). As studies evident by subclinical immunotherapies(139), antigen exposure and presentation by oral immune cells modulate systemic immune tolerance. The oral cavity is colonized with a complex microbial community that is directly connected to the gut microbiota both in early life and during pathogenic reaction(140,141). The composition of oral microbiota is influenced by birth mode and parents. Data showed that the composition of oral microbiota has distinct colonization patterns between C-section and vaginally delivered infants with vaginally born babies having a higher number of taxa(142). In addition, a recent study found that during 18 months of age, oral microbiota of infants was influenced by their parents and shared commensal and diseases related bacteria(143). This may be why breastfeeding and exposure to diverse microbial environments such as farms and big homes are important for decreasing the incidence of allergic diseases in infants. In the same time, study showed that residential microbiomes favor the crosstalk between innate myeloid and lymphoid cells that contributes to immune homeostasis in the gut and the development of oral tolerances to oral antigens(144).

From the perspective of gut microbiota, a previous study indicated that infants with cow's milk allergy had a relatively more abundant bacterial taxa, particularly anaerobics, compared to healthy controls after 6 months of milk formula feeding(145). More precisely, according to this study, gut microbiota of infants with CMA had higher concentrations of Lactobacilli and lower concentrations of Enterobacteria and Bifidobacteria. Infants whose CMA resolved by 8 years of age had an enhanced Clostridia and Firmicutes rate

in their gut(146). The gut microbiota of children with egg allergy had a greater abundance of certain genera compared to healthy ones, namely Lachnospiraceae and Ruminococcaceae(147). According to a recent study, involving 14 children with food allergy and 87 children with food allergens sensitization, resulted that Dorea, Haemophilus, Dialister, and Clostridium genera were reduced in latter participants, while the genera Citrobacter, Lactococcus, Oscillospira, and Dorea were belittled in participants with food allergy(148). Furthermore, data showed that, compared to healthy controls, the gut microbiota of peanut or tree nut allergy patients had a decreased richness and increased concentration of Bacteroides species(149).

Germ-free mice are ideal for studying gut microbiota related human diseases. Indeed, the role of gut microbiota in the development of CMA is proven to be prominent. Study showed that germ-free mice were protected from developing susceptibility to CMA if colonized with gut microbiota from healthy infants(150). Furthermore, transferring specific bacterial strains, Bifidobacterium or Clostridium, to mice was shown to reduce the risk of food sensitization by inducing mucosal Treg(151). Study also showed that Clostridia can stimulate innate lymphoid cells to produce IL-22, which contributes to straightening the epithelial barrier and decreasing the permeability of the intestine to dietary proteins(152). Some functional effects of Clostridia in food allergy may also exert via their fermentation metabolites such as butyrate, a SCFA that is known for its role on immunoregulatory and tolerogenic properties(153–158). In addition, butyrate is the only SCFA produced exclusively by gut microbial fermentation, while others are influenced by host metabolism(159). Recent findings support the hypothesis that butyrate might contribute to the development of immune oral tolerance and in the prevention and treatment of food allergies(160–162).

Previous human and animal studies established the association between oral and gut microbiota and food allergy. Although the mechanisms involved are complex and dynamic, they also underline the possibility of preventing and treating food allergy by microbial modulation. For example, a study showed that compared to non-supplemented hypoallergenic milk formula, supplementing with hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG promoted CMA resolution at 12, 24, and 36 months(163), which was found to enrich butyrate producing bacterial strains(153). Using an amino-acid based formula that contained a specific synbiotics, a combination of prebiotic blend of fructooligosaccharides and the probiotic strain Bifidobacterium breve M-16V, has been shown to modulate the gut microbiota and its metabolic activities in infants with non-IgE mediated CMA(164–166). In addition, a study indicated that oral supplementation with Lactobacillus rhamnosus GG could enhance the efficacy of oral immunotherapy in inducing peanut tolerance and immune changes in children with peanut allergy(167). However, this was an uncontrolled study, future studies including a control group are needed to further determine such results.

Fecal microbiota transplantation is another potential therapeutic approach for food allergy. Studies showed that re-establishing the gut microbiota of the patients can ameliorate the allergic symptoms by increasing microbiota diversity in FMT trials(168,169). Dysbiosis of gut microbiota leads to development of food allergy (146), thereupon, restoration of immune homeostasis and reconstruction of the impaired gut microbiota barrier by FMT may be able to promote the development of oral tolerance(168).

Conclusion

Microbiomes during pregnancy and infant early life are both crucial for the development of a healthy immune system and disease protection. The perturbation of microbiomes, either in maternal or infants, can have various harmful effects on immune health, contributing to the development of allergic diseases. Although recent studies have deepened our understanding of the relationships between maternal, infant microbiome, and immune system in allergic diseases, the mechanisms involved at molecular levels remain unelucidated. Indeed, allergic disease is not a single disease rather a result of complex microbial and immune interactions involving both mother and infant. Such complexity, on the contrary, gives us opportunities for intervention and modulation both during pregnancy and early infant life to decrease allergic symptoms. Therefore, understanding the mechanisms involved is utmost important for developing effective and safe prevention strategies for allergic diseases.

Figure legends:

Figure 1. Maternal influencing factors for development of allergic diseases in infants. Maternal infectious diseases(36,37), asthma(38), antibiotic exposure(39,40), and high fat (energy) diet increase the risk of asthma in infants. High fiber diet(41), and Vitamin D(42) supplement during pregnancy could decrease the rate of asthma in children. Maternal stress(43,44) and high age(45) contribute to the development of food allergy in infants. High energy diet during pregnancy increases the risk of AD in infants(46), while probiotics or a mixture of probiotics protects infants from AD risk(47). High maternal age and certain geographic location (i. e., Asia) closely related to increased infant allergic sensitization(48).

Figure 2. Influencing factors in the development of allergic diseases in infancy. Factors such as antibiotic exposure(68), preterm birth(69), formula feeding(70), and cesarean section delivery(71) increase the development of asthma in infants, while living in a big family(72) and farming environment(73) decrease asthma incidents. Increased birth weight(74) and combined feeding of breast milk and formula(75) increase food allergy development in childhood.

Figure 3. The role of maternal gut and milk microbiota and infant gut and lung microbiota in the development of asthma.

Figure 4. The role of maternal gut and milk microbiota and infant gut and skin microbiota in the development of AD.

Figure 5. The role of maternal gut and milk microbiota and infant gut and oral microbiota in the development of FA.

Competing interests

None of the authors have a financial interest in any of the products, devices, or Materials mentioned in this manuscript. The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTION

Conceptualization: Fu YH, Zhang NS.

Funding acquisition: Zhang NS.

Supervision: Fu YH, Zhang NS.

Visualization: Tuniyazi M.

Writing - original draft: Tuniyazi M.

Writing - review & editing: Hu XY, Li S.

References:

1. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases.*N Engl J Med* 2002;**347**:911–920.

2. Ren J, Xu J, Zhang P, Bao Y. Prevalence and Risk Factors of Asthma in Preschool Children in Shanghai, China: A Cross-Sectional Study. Frontiers in Pediatrics. 2022;**9**. doi:10.3389/fped.2021.793452

3. Sbihi H, Boutin RC, Cutler C, Suen M, Finlay BB, Turvey SE. Thinking bigger: How early-life environmental exposures shape the gut microbiome and influence the development of asthma and allergic disease. *Allergy*2019;**74**:2103–2115.

4. Coyte KZ, Rao C, Rakoff-Nahoum S, Foster KR. Ecological rules for the assembly of microbiome communities. *PLoS Biol* 2021;**19**:e3001116.

5. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. *Cell* 2012;**148**:1258–1270.

6. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nat Rev Neurosci* 2012;**13**:701–712.

7. Sugahara H, Odamaki T, Hashikura N, Abe F, Xiao J-Z. Differences in folate production by bifidobacteria of different origins. *Biosci Microbiota Food Health* 2015;**34**:87–93.

8. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I et al. Gut microbiota functions: metabolism of nutrients and other food components. European Journal of Nutrition. 2018;**57**:1–24.

9. Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H et al. The maternal microbiota drives early postnatal innate immune development.*Science* 2016;**351**:1296–1302.

10. Francino M. Early Development of the Gut Microbiota and Immune Health. Pathogens. 2014;**3**:769–790.

11. Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nature Medicine. 2016;**22**:713–722.

12. Peroni DG, Nuzzi G, Trambusti I, Di Cicco ME, Comberiati P. Microbiome Composition and Its Impact on the Development of Allergic Diseases. Frontiers in Immunology. 2020;**11**. doi:10.3389/fimmu.2020.00700

13. Gensollen T, Blumberg RS. Correlation between early-life regulation of the immune system by microbiota and allergy development. *J Allergy Clin Immunol*2017;**139**:1084–1091.

14. Stokholm J, Thorsen J, Chawes BL, Schjørring S, Krogfelt KA, Bønnelykke K et al. Cesarean section changes neonatal gut colonization. *J Allergy Clin Immunol*2016;**138**:881–889.e2.

15. Shaterian N, Abdi F, Ghavidel N, Alidost F. Role of cesarean section in the development of neonatal gut microbiota: A systematic review. Open Medicine. 2021;**16**:624–639.

16. Kim G, Bae J, Kim MJ, Kwon H, Park G, Kim S-J et al. Delayed Establishment of Gut Microbiota in Infants Delivered by Cesarean Section. *Front Microbiol*2020;**11**:2099.

17. Ma J, Li Z, Zhang W, Zhang C, Zhang Y, Mei H et al. Comparison of gut microbiota in exclusively breast-fed and formula-fed babies: a study of 91 term infants. Scientific Reports. 2020;**10**. doi:10.1038/s41598-020-72635-x

18. Zhong H, Wang X-G, Wang J, Chen Y-J, Qin H-L, Yang R. Impact of probiotics supplement on the gut microbiota in neonates with antibiotic exposure: an open-label single-center randomized parallel controlled study. *World J Pediatr* 2021;**17**:385–393.

19. Yousuf EI, Carvalho M, Dizzell SE, Kim S, Gunn E, Twiss J et al. Persistence of Suspected Probiotic Organisms in Preterm Infant Gut Microbiota Weeks After Probiotic Supplementation in the NICU. *Front Microbiol*2020;**11**:574137.

20. Berardi A, Rossi K, Pizzi C, Baronciani D, Venturelli C, Ferrari F et al. Absence of neonatal streptococcal colonization after planned cesarean section. Acta Obstetricia et Gynecologica Scandinavica. 2006;**85**:1012–1013.

21. Wilson BC, Butler ÉM, Grigg CP, Derraik JGB, Chiavaroli V, Walker N et al. Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised placebo-controlled trial. *EBioMedicine* 2021;**69**:103443.

22. Korpela K, Helve O, Kolho K-L, Saisto T, Skogberg K, Dikareva E et al. Maternal Fecal Microbiota Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut Microbial Development: A Proof-of-Concept Study. *Cell*2020;**183**:324–334.e5.

23. Shao Y, Forster SC, Tsaliki E, Vervier K, Strang A, Simpson N et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth.*Nature* 2019;**574**:117–121.

24. Reyman M, van Houten MA, van Baarle D, Bosch AATM, Man WH, Chu MLJN et al. Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life. *Nat Commun* 2019;**10**:4997.

25. Simpson MR, Avershina E, Storrø O, Johnsen R, Rudi K, Øien T. Breastfeeding-associated microbiota in human milk following supplementation with Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5, and Bifidobacterium animalis ssp. lactis Bb-12. *J Dairy Sci* 2018;**101**:889–899.

26. Ferretti P, Pasolli E, Tett A, Asnicar F, Gorfer V, Fedi S et al. Mother-to-Infant Microbial Transmission from Different Body Sites Shapes the Developing Infant Gut Microbiome. *Cell Host Microbe* 2018;**24**:133–145.e5.

27. Niu J, Xu L, Qian Y, Sun Z, Yu D, Huang J et al. Evolution of the Gut Microbiome in Early Childhood: A Cross-Sectional Study of Chinese Children. *Front Microbiol* 2020;**11**:439.

28. Vandenplas Y, Carnielli VP, Ksiazyk J, Sanchez Luna M, Migacheva N, Mosselmans JM et al. Factors affecting early-life intestinal microbiota development. Nutrition. 2020;**78**:110812.

29. Hoyen C. Factors Influencing the Composition of the Intestinal Microbiota in Early Infancy. Yearbook of Neonatal and Perinatal Medicine. 2007;**2007**:202–203.

30. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I et al. Factors Influencing the Composition of the Intestinal Microbiota in Early Infancy. Pediatrics. 2006;**118**:511–521.

31. Dierikx TH, Visser DH, Benninga MA, van Kaam AHLC, de Boer NKH, de Vries R et al. The influence of prenatal and intrapartum antibiotics on intestinal microbiota colonisation in infants: A systematic review. *J Infect* 2020;**81**:190–204.

32. Milliken S, Allen RM, Lamont RF. The role of antimicrobial treatment during pregnancy on the neonatal gut microbiome and the development of atopy, asthma, allergy and obesity in childhood. *Expert Opin Drug Saf* 2019;**18**:173–185.

33. Junca H, Pieper DH, Medina E. The emerging potential of microbiome transplantation on human health interventions. *Comput Struct Biotechnol J* 2022;**20**:615–627.

34. Grier A, McDavid A, Wang B, Qiu X, Java J, Bandyopadhyay S et al. Neonatal gut and respiratory microbiota: coordinated development through time and space. Microbiome. 2018;**6**. doi:10.1186/s40168-018-0566-5

35. Robertson RC, Manges AR, Finlay BB, Prendergast AJ. The Human Microbiome and Child Growth - First 1000 Days and Beyond. *Trends Microbiol* 2019;**27**:131–147.

36. Wu P, Feldman AS, Rosas-Salazar C, James K, Escobar G, Gebretsadik T et al. Relative Importance and Additive Effects of Maternal and Infant Risk Factors on Childhood Asthma. *PLoS One* 2016;**11**:e0151705.

37. Xu B, Pekkanen J, Jarvelin MR, Olsen P, Hartikainen AL. Maternal infections in pregnancy and the development of asthma among offspring. International Journal of Epidemiology. 1999;**28**:723–727.

38. Sly PD. Maternal Asthma, Pregnancy Complications, and Offspring Wheeze. Untangling the Web. Am. J. Respir. Crit. Care Med. 2019;**199**:1–2.

39. Blaser MJ, Bello MGD. Maternal antibiotic use and risk of asthma in offspring. Lancet Respir Med. 2014;**2**:e16.

40. Loewen K, Monchka B, Mahmud SM, Jong G 't, Azad MB. Prenatal antibiotic exposure and childhood asthma: a population-based study. European Respiratory Journal. 2018;**52**:1702070.

41. Gray LEK, O'Hely M, Ranganathan S, Sly PD, Vuillermin P. The Maternal Diet, Gut Bacteria, and Bacterial Metabolites during Pregnancy Influence Offspring Asthma. *Front Immunol* 2017;**8**:365.

42. Viljoen K, Segurado R, O'Brien J, Murrin C, Mehegan J, Kelleher CC. Pregnancy diet and offspring asthma risk over a 10-year period: the Lifeways Cross Generation Cohort Study, Ireland. BMJ Open. 2018;**8**:e017013.

43. Polloni L, Ferruzza E, Ronconi L, Lazzarotto F, Toniolo A, Bonaguro R et al. Perinatal stress and food allergy: a preliminary study on maternal reports. Psychology, Health & Medicine. 2015;**20**:732–741.

44. Olsson Mägi C-A, Bjerg Bäcklund A, Lødrup Carlsen K, Almqvist C, Carlsen K-H, Granum B et al. Allergic disease and risk of stress in pregnant women: a PreventADALL study. *ERJ Open Res* 2020;**6**. doi:10.1183/23120541.00175-2020

45. Dioun AF, Harris SK, Hibberd PL. Is maternal age at delivery related to childhood food allergy? *Pediatr Allergy Immunol* 2003;**14**:307–311.

46. Saito K, Yokoyama T, Miyake Y, Sasaki S, Tanaka K, Ohya Y et al. Maternal meat and fat consumption during pregnancy and suspected atopic eczema in Japanese infants aged 3-4 months: the Osaka Maternal and Child Health Study.*Pediatr Allergy Immunol* 2010;**21**:38–46.

47. Sestito S, D'Auria E, Baldassarre ME, Salvatore S, Tallarico V, Stefanelli E et al. The Role of Prebiotics and Probiotics in Prevention of Allergic Diseases in Infants. *Front Pediatr* 2020;**8**:583946.

48. Schäfer S, Liu A, Campbell D, Nanan R. Analysis of maternal and perinatal determinants of allergic sensitization in childhood. *Allergy Asthma Clin Immunol*2020;**16**:71.

49. Aversa Z, Atkinson EJ, Schafer MJ, Theiler RN, Rocca WA, Blaser MJ et al. Association of Infant Antibiotic Exposure With Childhood Health Outcomes. *Mayo Clin Proc* 2021;**96**:66–77.

50. Moreau MC, Ducluzeau R, Guy-Grand D, Muller MC. Increase in the population of duodenal immuno-globulin A plasmocytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. *Infect Immun* 1978;**21**:532–539.

51. Franchi L, Warner N, Viani K, Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunological Reviews. 2009;**227**:106–128.

52. Baba N, Samson S, Bourdet-Sicard R, Rubio M, Sarfati M. Commensal bacteria trigger a full dendritic cell maturation program that promotes the expansion of non-Tr1 suppressor T cells. *J Leukoc Biol* 2008;**84**:468–476.

53. Fulde M, Hornef MW. Maturation of the enteric mucosal innate immune system during the postnatal period. *Immunol Rev* 2014;**260**:21–34.

54. Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM et al. Microbial colonization influences early B-lineage development in the gut lamina propria. *Nature* 2013;**501**:112–115.

55. Inman CF, Laycock GM, Mitchard L, Harley R, Warwick J, Burt R et al. Neonatal colonisation expands a specific intestinal antigen-presenting cell subset prior to CD4 T-cell expansion, without altering T-cell repertoire. *PLoS One* 2012;**7**:e33707.

56. Okogbule-Wonodi AC, Li G, Anand B, Luzina IG, Atamas SP, Blanchard T. Human foetal intestinal fibroblasts are hyper-responsive to lipopolysaccharide stimulation.*Dig Liver Dis* 2012;**44**:18–23.

57. Sansonetti PJ. To be or not to be a pathogen: that is the mucosally relevant question.*Mucosal Immunol* 2011;**4**:8–14.

58. Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang Y-C et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. *Science* 2010;**329**:849–853.

59. Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S et al. NLRC4-driven production of IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. *Nat Immunol* 2012;**13**:449–456.

60. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology. 2009;**9**:313–323.

61. Christmann BS, Abrahamsson TR, Bernstein CN, Duck LW, Mannon PJ, Berg G et al. Human seroreactivity to gut microbiota antigens. *J Allergy Clin Immunol* 2015;**136**:1378–1386.e1–e5.

62. Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. *Allergol Int* 2017;**66**:515–522.

63. West CE, Rydén P, Lundin D, Engstrand L, Tulic MK, Prescott SL. Gut microbiome and innate immune response patterns in IgE-associated eczema. *Clin Exp Allergy* 2015;**45**:1419–1429.

64. Yiu JHC, Dorweiler B, Woo CW. Interaction between gut microbiota and toll-like receptor: from immunity to metabolism. *J Mol Med* 2017;**95**:13–20.

65. Sun L, Liu W, Zhang L-J. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis. *J Immunol Res* 2019;**2019**:1824624.

66. Fujimura KE, Sitarik AR, Havstad S, Lin DL, Levan S, Fadrosh D et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nature Medicine. 2016;**22**:1187–1191.

67. Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK et al. Maturation of the gut microbiome and risk of asthma in childhood. *Nat Commun* 2018;**9**:141.

68. Ni J, Friedman H, Boyd BC, McGurn A, Babinski P, Markossian T et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. *BMC Pediatr* 2019;**19**:225.

69. Zhang J, Ma C, Yang A, Zhang R, Gong J, Mo F. Is preterm birth associated with asthma among children from birth to 17 years old? -A study based on 2011-2012 US National Survey of Children's Health. Italian Journal of Pediatrics. 2018;**44**. doi:10.1186/s13052-018-0583-9

70. El-Heneidy A, Abdel-Rahman M, Mihala G, Ross L, Comans T. Milk Other Than Breast Milk and the Development of Asthma in Children 3 Years of Age. A Birth Cohort Study (2006–2011). Nutrients. 2018;**10**:1798.

71. Roduit C, Scholtens S, de Jongste JC, Wijga AH, Gerritsen J, Postma DS et al. Asthma at 8 years of age in children born by caesarean section. Thorax. 2009;**64**:107–113.

72. Goldberg S, Israeli E, Schwartz S, Shochat T, Izbicki G, Toker-Maimon O et al. Asthma prevalence, family size, and birth order. *Chest* 2007;**131**:1747–1752.

73. Andersén H, Ilmarinen P, Honkamäki J, Tuomisto LE, Hisinger-Mölkänen H, Backman H et al. Influence of Childhood Exposure to a Farming Environment on Age at Asthma Diagnosis in a Population-Based Study. Journal of Asthma and Allergy. 2021;**14**:1081–1091.

74. Wooldridge AL, McMillan M, Kaur M, Giles LC, Marshall HS, Gatford KL. Relationship between birth weight or fetal growth rate and postnatal allergy: A systematic review. Journal of Allergy and Clinical Immunology. 2019;**144**:1703–1713.

75. Mathias JMG, Zhang H, Karmaus W, Soto-Ramirez N, Shen Y. Mixed Infant Feeding - Direct Breastfeeding, Pumping and Feeding, and Formula Food Poses a Risk for Food Allergy in Early Childhood. Journal of Allergy and Clinical Immunology. 2017;**139**:AB385.

76. Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The Role of Lung and Gut Microbiota in the Pathology of Asthma. *Immunity* 2020;**52**:241–255.

77. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nature Reviews Genetics. 2012;**13**:260–270.

78. Prescott SL. Early-life environmental determinants of allergic diseases and the wider pandemic of inflammatory noncommunicable diseases. *J Allergy Clin Immunol* 2013;**131**:23–30.

79. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P et al. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell Host Microbe* 2015;**17**:852.

80. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M et al. Human gut microbiome viewed across age and geography. *Nature* 2012;**486**:222–227.

81. Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. *Nature* 2014;**510**:417–421.

82. Bokulich NA, Chung J, Battaglia T, Henderson N, Jay M, Li H et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. *Sci Transl Med* 2016;**8**:343ra82.

83. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. *Science* 2016;**352**:539–544.

84. Geervliet M. A window of opportunity : Modulation of the porcine gut microbiota and immune system by feed additives in early life. doi:10.18174/553257

85. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM, Cho I et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell* 2014;**158**:705–721.

86. Bisgaard H, Li N, Bonnelykke K, Chawes BLK, Skov T, Paludan-Müller G et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. *J Allergy Clin Immunol* 2011;**128**:646–652.e1–e5.

87. Nowak-Wegrzyn A. Allergy Development and the Intestinal Microflora During the First Year of Life. Pediatrics. 2002;**110**:431–431.

88. Ege MJ, Mayer M, Normand A-C, Genuneit J, Cookson WOCM, Braun-Fahrländer C et al. Exposure to environmental microorganisms and childhood asthma. *N Engl J Med* 2011;**364**:701–709.

89. Penders J, Gerhold K, Thijs C, Zimmermann K, Wahn U, Lau S et al. New insights into the hygiene hypothesis in allergic diseases: mediation of sibling and birth mode effects by the gut microbiota. *Gut Microbes* 2014;**5**:239–244.

90. Arrieta M-C, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch S et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. *Sci Transl Med* 2015;**7**:307ra152.

91. Smart BA. Childhood Asthma After Bacterial Colonization of the Airway in Neonates. Pediatrics. 2008;**122**:S206–S207.

92. Mansbach JM, Luna PN, Shaw CA, Hasegawa K, Petrosino JF, Piedra PA et al. Increased Moraxella and Streptococcus species abundance after severe bronchiolitis is associated with recurrent wheezing. *J Allergy Clin Immunol* 2020;**145**:518–527.e8.

93. Thorsen J, Rasmussen MA, Waage J, Mortensen M, Brejnrod A, Bønnelykke K et al. Infant airway microbiota and topical immune perturbations in the origins of childhood asthma. *Nat Commun* 2019;**10**:5001.

94. Ranucci G, Buccigrossi V, de Freitas MB, Guarino A, Giannattasio A. Early-Life Intestine Microbiota and Lung Health in Children. *J Immunol Res* 2017;**2017**:8450496.

95. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nat Med* 2009;**15**:410–416.

96. Schuijs MJ, Willart MA, Vergote K, Gras D, Deswarte K, Ege MJ et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. *Science* 2015;**349**:1106–1110.

97. Noci VL, Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F et al. Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Reports. 2018;**24**:3528–3538.

98. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C et al. Disordered microbial communities in asthmatic airways. *PLoS One* 2010;**5**:e8578.

99. Di Cicco M, Pistello M, Jacinto T, Ragazzo V, Piras M, Freer G et al. Does lung microbiome play a causal or casual role in asthma? *Pediatr Pulmonol* 2018;**53**:1340–1345.

100. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD et al. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. *Nat Med* 2014;**20**:642–647.

101. Genuneit J. Exposure to farming environments in childhood and asthma and wheeze in rural populations: a systematic review with meta-analysis. *Pediatr Allergy Immunol* 2012;**23**:509–518.

102. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;**17**:704–715.

103. Mulder B, Pouwels KB, Schuiling-Veninga CCM, Bos HJ, de Vries TW, Jick SS et al. Antibiotic use during pregnancy and asthma in preschool children: the influence of confounding. *Clin Exp Allergy* 2016;**46**:1214–1226.

104. Zhao D, Su H, Cheng J, Wang X, Xie M, Li K et al. Prenatal antibiotic use and risk of childhood wheeze/asthma: A meta-analysis. *Pediatr Allergy Immunol* 2015;**26**:756–764.

105. Yoshida S, Ide K, Takeuchi M, Kawakami K. Prenatal and early-life antibiotic use and risk of childhood asthma: A retrospective cohort study. Pediatric Allergy and Immunology. 2018;**29**:490–495.

106. Alhasan MM, Cait AM, Heimesaat MM, Blaut M, Klopfleisch R, Wedel A et al. Antibiotic use during pregnancy increases offspring asthma severity in a dose-dependent manner. Allergy. 2020;**75**:1979–1990.

107. Durack J, Kimes NE, Lin DL, Rauch M, McKean M, McCauley K et al. Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation. *Nat Commun* 2018;**9**:707.

108. Durack J, Kimes NE, Lin D, McKean M, Rauch M, Cabana MD et al. Early-life Lactobacillus rhamnosus GG Supplementation of High-risk for Asthma Infants Reprograms Gut Microbiota Development and promotes regulatory T-cells. Journal of Allergy and Clinical Immunology. 2017;**139**:AB15.

109. Calder P. Faculty of 1000 evaluation for Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. F1000 - Post-publication peer review of the biomedical literature. 2013. doi:10.3410/f.718059905.793482506

110. Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, Cox LM, Amir A, Gonzalez A et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. *Nat Med* 2016;**22**:250–253.

111. Cunnington AJ, Sim K, Deierl A, Kroll JS, Brannigan E, Darby J. 'Vaginal seeding' of infants born by caesarean section. *BMJ* 2016;**352**:i227.

112. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nature Medicine. 2014;**20**:159–166.

113. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol* 2011;**17**:1519–1528.

114. Udkoff J, Waldman A, Ahluwalia J, Borok J, Eichenfield LF. Current and emerging topical therapies for atopic dermatitis. *Clin Dermatol*2017;**35**:375–382.

115. Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. *Ann Allergy Asthma Immunol*2018;**120**:34–41.

116. Wollina U. Microbiome in atopic dermatitis. *Clin Cosmet Investig Dermatol*2017;**10**:51–56.

117. Tong J, Li HY. The human skin microbiome. The human microbiota and microbiome. 2014;:72–89.

118. Huang YJ, Marsland BJ, Bunyavanich S, O'Mahony L, Leung DYM, Muraro A et al. The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology.*J Allergy Clin Immunol* 2017;**139**:1099–1110.

119. Baurecht H, Ruhlemann MC, Rodriguez E, Thielking F, Harder I, Erkens A-S et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. *J Allergy Clin Immunol* 2018;**141**:1668–1676.e16.

120. Malhotra N, Yoon J, Leyva-Castillo JM, Galand C, Archer N, Miller LS et al. IL-22 derived from γδ T cells restricts Staphylococcus aureus infection of mechanically injured skin. *J Allergy Clin Immunol*2016;**138**:1098–1107.e3.

121. Kennedy EA, Connolly J, Hourihane JO, Fallon PG, McLean WHI, Murray D et al. Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. *J Allergy Clin Immunol*2017;**139**:166–172.

122. Salava A, Lauerma A. Role of the skin microbiome in atopic dermatitis. Clinical and Translational Allergy. 2014;**4**:33.

123. Laubereau B, Filipiak-Pittroff B, von Berg A, Grübl A, Reinhardt D, Wichmann HE et al. Caesarean section and gastrointestinal symptoms, atopic dermatitis, and sensitisation during the first year of life. *Arch Dis Child*2004;**89**:993–997.

124. Richards M, Ferber J, Chen H, Swor E, Quesenberry CP, Li D-K et al. Caesarean delivery and the risk of atopic dermatitis in children. *Clin Exp Allergy*2020;**50**:805–814.

125. Lasley MV. Caesarean Delivery and the Risk of Atopic Dermatitis in Children. Pediatrics. 2021;**148**:S5–S6.

126. Shin H, Pei Z, Martinez KA 2nd, Rivera-Vinas JI, Mendez K, Cavallin H et al. The first microbial environment of infants born by C-section: the operating room microbes.*Microbiome* 2015;**3**:59.

127. Hendricks AJ, Mills BW, Shi VY. Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Journal of Dermatological Science. 2019;**95**:56–61.

128. Craig JM. Atopic dermatitis and the intestinal microbiota in humans and dogs. *Vet Med Sci* 2016;**2**:95–105.

129. Zuo W, Sun C. The Role of the Intestinal Microbiota in Atopic Dermatitis. International Journal of Dermatology and Venereology. 2021;**Publish Ahead of Print**. doi:10.1097/jd9.0000000000000152

130. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. *J Allergy Clin Immunol* 2003;**111**:587–591.

131. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007;**56**:661–667.

132. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol* 2012;**129**:434–440, 440.e1–e2.

133. Forno E, Onderdonk AB, McCracken J, Litonjua AA, Laskey D, Delaney ML et al. Diversity of the Gut Microbiota and Eczema in Infants. D47. NEONATAL AND RARE LUNG DISEASES. 2009. doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5981

134. Galazzo G, van Best N, Bervoets L, Dapaah IO, Savelkoul PH, Hornef MW et al. Development of the Microbiota and Associations With Birth Mode, Diet, and Atopic Disorders in a Longitudinal Analysis of Stool Samples, Collected From Infancy Through Early Childhood. Gastroenterology. 2020;**158**:1584–1596.

135. Rø ADB, Simpson MR, Rø TB, Storrø O, Johnsen R, Videm V et al. Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation. *Clin Exp Allergy* 2017;**47**:1014–1021.

136. Kim J-H, Kim K, Kim W. Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy. Experimental & Molecular Medicine. 2021;**53**:907–916.

137. Mashiah J, Karady T, Fliss-Isakov N, Sprecher E, Slodownik D, Artzi O et al. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate-to-severe atopic dermatitis. *Immun Inflamm Dis* 2022;**10**:e570.

138. Allam J-P, Duan Y, Winter J, Stojanovski G, Fronhoffs F, Wenghoefer M et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. *Allergy* 2011;**66**:532–539.

139. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. *J Allergy Clin Immunol Pract* 2013;**1**:228–241.

140. Consortium THMP, The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;**486**:207–214.

141. Xiao J, Fiscella KA, Gill SR. Oral microbiome: possible harbinger for children's health. International Journal of Oral Science. 2020;**12**. doi:10.1038/s41368-020-0082-x

142. Lif Holgerson P, Harnevik L, Hernell O, Tanner ACR, Johansson I. Mode of birth delivery affects oral microbiota in infants. *J Dent Res* 2011;**90**:1183–1188.

143. Jo R, Yama K, Aita Y, Tsutsumi K, Ishihara C, Maruyama M et al. Comparison of oral microbiome profiles in 18-month-old infants and their parents. *Sci Rep* 2021;**11**:861.

144. Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. *Science* 2014;**343**:1249288.

145. Thompson-Chagoyan OC, Vieites JM, Maldonado J, Edwards C, Gil A. Changes in faecal microbiota of infants with cow's milk protein allergy - a Spanish prospective case-control 6-month follow-up study. Pediatric Allergy and Immunology. 2010;**21**:e394–e400.

146. Bunyavanich S, Shen N, Grishin A, Wood R, Burks W, Dawson P et al. Early-life gut microbiome composition and milk allergy resolution. Journal of Allergy and Clinical Immunology. 2016;**138**:1122–1130.

147. Fazlollahi M, Chun Y, Grishin A, Wood RA, Burks AW, Dawson P et al. Early-life gut microbiome and egg allergy. *Allergy* 2018;**73**:1515–1524.

148. Savage JH, Lee-Sarwar KA, Sordillo J, Bunyavanich S, Zhou Y, O'Connor G et al. A prospective microbiome-wide association study of food sensitization and food allergy in early childhood. *Allergy* 2018;**73**:145–152.

149. Hua X, Goedert JJ, Pu A, Yu G, Shi J. Allergy associations with the adult fecal microbiota: Analysis of the American Gut Project. *EBioMedicine* 2016;**3**:172–179.

150. Feehley T, Plunkett CH, Bao R, Choi Hong SM, Culleen E, Belda-Ferre P et al. Healthy infants harbor intestinal bacteria that protect against food allergy. *Nat Med* 2019;**25**:448–453.

151. Lyons A, O'Mahony D, O'Brien F, MacSharry J, Sheil B, Ceddia M et al. Bacterial strain-specific induction of Foxp3 T regulatory cells is protective in murine allergy models. Clinical & Experimental Allergy. 2010. doi:10.1111/j.1365-2222.2009.03437.x

152. Stefka AT, Feehley T, Tripathi P, Qiu J, McCoy K, Mazmanian SK et al. Commensal bacteria protect against food allergen sensitization. *Proc Natl Acad Sci U S A* 2014;**111**:13145–13150.

153. Canani RB, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. The ISME Journal. 2016;**10**:742–750.

154. Guest JF, Fuller GW. Effectiveness of using an extensively hydrolyzed casein formula supplemented with Lactobacillus rhamnosus GG compared with an extensively hydrolysed whey formula in managing cow's milk protein allergic infants. Journal of Comparative Effectiveness Research. 2019;**8**:1317–1326.

155. Luu M, Visekruna A. Short-chain fatty acids: Bacterial messengers modulating the immunometabolism of T cells. *Eur J Immunol* 2019;**49**:842–848.

156. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013;**504**:451–455.

157. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013;**504**:446–450.

158. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis. Science. 2013;**341**:569–573.

159. Cait A, Cardenas E, Dimitriu PA, Amenyogbe N, Dai D, Cait J et al. Reduced genetic potential for butyrate fermentation in the gut microbiome of infants who develop allergic sensitization. *J Allergy Clin Immunol* 2019;**144**:1638–1647.e3.

160. Urschel D, Hernandez-Trujillo V. Butyrate as a Bioactive Human Milk Protective Component Against Food Allergy. Pediatrics. 2021;**148**:S21–S22.

161. Luu M, Monning H, Visekruna A. Exploring the Molecular Mechanisms Underlying the Protective Effects of Microbial SCFAs on Intestinal Tolerance and Food Allergy. *Front Immunol* 2020;**11**:1225.

162. Di Costanzo M, Carucci L, Berni Canani R, Biasucci G. Gut Microbiome Modulation for Preventing and Treating Pediatric Food Allergies. *Int J Mol Sci* 2020;**21**. doi:10.3390/ijms21155275

163. Canani RB, Di Costanzo M, Bedogni G, Amoroso A, Cosenza L, Di Scala C et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial. Journal of Allergy and Clinical Immunology. 2017;**139**:1906–1913.e4.

164. Wopereis H, the ASSIGN study group, van Ampting MTJ, Cetinyurek-Yavuz A, Slump R, Candy DCA et al. A specific synbiotic-containing amino acid-based formula restores gut microbiota in non-IgE mediated cow's milk allergic infants: a randomized controlled trial. Clinical and Translational Allergy. 2019;**9**. doi:10.1186/s13601-019-0267-6

165. Fox AT, ASSIGN study group, Wopereis H, Van Ampting MTJ, Oude Nijhuis MM, Butt AM et al. A specific synbiotic-containing amino acid-based formula in dietary management of cow's milk allergy: a randomized controlled trial. Clinical and Translational Allergy. 2019;**9**. doi:10.1186/s13601-019-0241-3

166. Candy DCA, Van Ampting MTJ, Oude Nijhuis MM, Wopereis H, Butt AM, Peroni DG et al. A synbiotic-containing amino-acid-based formula improves gut microbiota in non-IgE-mediated allergic infants. *Pediatr Res* 2018;**83**:677–686.

167. Tang MLK, Ponsonby A-L, Orsini F, Tey D, Robinson M, Su EL et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol* 2015;**135**:737–744.e8.

168. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. *Nat Rev Gastroenterol Hepatol* 2011;**9**:88–96.

169. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therapeutic Advances in Gastroenterology. 2016;**9**:229–239.

Figure 3. The role of maternal gut and milk microbiota and infant gut and lung microbiota in the development of asthma.

Figure 4. The role of maternal gut and milk microbiota and infant gut and skin microbiota in the development of AD.

Atopic dermatitis

Mother

Baby

Gut microbiota

Milk microbiota

Gut microbiota

Skin microbiota

↓ Actinobacteria

↓ Coprococcuseutactus

↓ Ruminococcus lactaris

↓ Uncultured Clostridiale

↓ Akkermansia muciniphila

↑ Prevotella

↓ Leptotrichia wadei

↑ Streptococcus anginosus

↓ Bifidobacterium B. breve

↓ Clostridium paraputrificum

↓ Uncultured Clostridiales

↓ Uncultured Lachnospiraceae

↓ Akkermansia muciniphila

↑ Bacteroides

↑ Dorea longicatena

↑ Faecalibacterium

↑ Ruminococcus lactaris

↑ Staphylococcus aureus

↓ Staphylococci coagulase-negative spp.

↓ Bifidobacteriaceae

↓ Bacteroides

Figure 5. The role of maternal gut and milk
microbiota and infant gut and oral microbiota
in the development of FA.

Food allergy

Mother

Baby

Gut
microbiota

Milk
microbiota

Gut
microbiota

Oral
microbiota

↓ Prevotella copri

↑ Proteobacteria

↑ Acinetobacter

↑ Pseudomonas

↑ Bacteroides
↑ Lachnospiracee
↓ Lactobacillus spp.
↑ Ruminociccaceae
↓ Dorea
↓ Lactococcus
↓ Dialister
↓ Oscillospira
↓ Enterobacteriaceae
↓ Clostridiaceae
↓ Bifidobacteriaceae
↓ Citrobacter

↑ Bacteroides
↑ Gemella
↑ Eubacterium
↑ Neisseria
↑ Lactobacillus
↑ Alloprevotella
↑ Corynebacterium
↑ Selenomonas
↑ Veillonella
↑ Megasphera
↑ Fusobacterium
↑ Lachnoanaerobaculum

19

Figure 1. Maternal influencing factors for development of allergic diseases in infants. Maternal infectious diseases(36,37), asthma(38), antibiotic exposure(39,40), and high fat (energy) diet increase the risk of asthma in infants. High fiber diet(41), and Vitamin D(42) supplement during pregnancy could decrease the rate of asthma in children. Maternal stress(43,44) and high age(45) contribute to the development of food allergy in infants. High energy diet during pregnancy increases the risk of AD in infants(46), while probiotics or a mixture of probiotics protects infants from AD risk(47). High maternal age and certain geographic location (i. e., Asia) closely related to increased infant allergic sensitization(48).

Figure 2. Influencing factors in the development of allergic diseases in infancy. Factors such as antibiotic exposure(68), preterm birth(69), formula feeding(70), and cesarean section delivery(71) increase the development of asthma in infants, while living in a big family(72) and farming environment(73) decrease asthma incidents. Increased birth weight(74) and combined feeding of breast milk and formula(75) increase food allergy development in childhood.